In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.


The free consultation period for this content is over.

It is now only available year-round to EAPC Ivory (& above) Members, Fellows of the ESC and Young combined Members

Relationship between cognitive impairment, left ventricle filling pressure and diastolic dysfunction in CAD patients

Session Poster Session 2

Speaker Maryna Dolzhenko

Congress : ESC Preventive Cardiology (Formerly EuroPrevent) 2019

  • Topic : preventive cardiology
  • Sub-topic : Secondary Prevention
  • Session type : Poster Session
  • FP Number : P549

Authors : MM Dolzhenko (Kiev,UA), OO Nudchenko (Kiev,UA), LI Yakovenko (Kiev,UA), SA Bondarchuk (Kiev,UA)

Authors:
MM Dolzhenko1 , OO Nudchenko1 , LI Yakovenko1 , SA Bondarchuk1 , 1National Medical Academy of Postgraduate Education, Cardiology - Kiev - Ukraine ,

Citation:

Background/Introduction. 

Cognitive impairment (CI) is a well-known predictor of mortality and readmissions in patients with coronary arteries disease (CAD) and heart failure (HF). But today, prevalence of CI is often underestimated. Therefore, evaluation of real prevalence of CI and it’s possible markers in CAD patients are very important.

Purpose.

Purpose of the study was to evaluate the prevalence of CI in patients with CAD and it’s relationship with diastolic dysfunction and left ventricle filling pressure (LVFP).

Methods.

For 110 patients with established CAD (prior myocardial infarction (MI), unstable angina (UA), percutaneous coronary intervention or coronary arteries bypass grafting) by Euroaspire V in Ukrainian cohort testing of cognitive functioning by validated scales – MMSE, MoCA – and echocardiography were performed. By results of echocardiography all patients were divided in four groups: I – E/e’ ratio<10, E/A>0,8; II – E/e’ ratio<10, E/A<0,8; III – E/e’ ratio – 10-14; IV – E/e’ ratio >14.

Results.

The average age of patients was 60.1 ± 8.74 years. 71.8% male patients, 28.2% of women. In 64,5% of cases, there was prior MI, and in 35,5% - unstable angina. There are no differences in age, diabetes mellitus prevalence, office blood pressure levels, left ventricle ejection fraction between groups were noted. Testing by MMSE scale showed, that 20,9% of patients had no CI, in 50% of patients mild CI was observed. Mild dementia was noted in 23,6% and dementia of moderate degree – in 5,45% of patients. Mean score by MMSE scale in I group was 25,7±2,57; II – 25,0±2,50, III– 23,4±3,04; IV – 21,1±2,69.  Comparison of groups showed that mean score by MMSE was significantly lower in III and IV groups (p1,3=0.0018, p1,4<0.0001). Negative correlation between E/e’ ratio and MMSE score was noted (r=-0.47). Mean score on the MoCA scale was in the first group 23.6 ± 3.30, in the second group - 22.5 ± 3.70, in the third - 21.4 ± 5.17, in the fourth - 17.9 ± 4.17 . In comparison with the first group, the significantly worse values are also noted in III I IV groups (p1,3 = 0,04, p1,4 = <0.0001). 

Conclusions.

In patients with diastolic function and high LVEF, no normal cognitive function by MMSE and MoCA scales was observed. In patients with diastolic dysfunction and elevated LVEF there are significantly lower rates of cognitive function than in patients with normal diastolic function. A negative correlation (r = -0.47) between E/e’ ratio and MMSE score was noted.



Based on your interests

Members get more

Join now
  • 1ESC Professional Members – access all resources from ESC Congress and ESC Asia with APSC & AFC
  • 2ESC Association Members (Ivory, Silver, Gold) – access your Association’s congress resources
  • 3Under 40 or in training - with a Combined Membership, access resources from all congresses
Join now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are